142 related articles for article (PubMed ID: 31290058)
1. Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
Yari M; Eslami M; Ghoshoon MB; Nezafat N; Ghasemi Y
Mol Biol Rep; 2019 Oct; 46(5):4751-4761. PubMed ID: 31290058
[TBL] [Abstract][Full Text] [Related]
2. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
3. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
Nguyen HA; Su Y; Lavie A
J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
[TBL] [Abstract][Full Text] [Related]
4. Recombinant deamidated mutants of Erwinia chrysanthemi L-asparaginase have similar or increased activity compared to wild-type enzyme.
Gervais D; Foote N
Mol Biotechnol; 2014 Oct; 56(10):865-77. PubMed ID: 24870616
[TBL] [Abstract][Full Text] [Related]
5. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
6. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
Gervais D; Corn T; Downer A; Smith S; Jennings A
AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
[TBL] [Abstract][Full Text] [Related]
7. In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
Zadeh Hosseingholi E; Neghabi N; Molavi G; Gheibi Hayat SM; Shahriarpour H
IUBMB Life; 2020 May; 72(5):991-1000. PubMed ID: 31981306
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
9. Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience.
Gervais D
Biologicals; 2020 Mar; 64():28-33. PubMed ID: 31959505
[TBL] [Abstract][Full Text] [Related]
10. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.
Zalewska-Szewczyk B; Gach A; Wyka K; Bodalski J; Młynarski W
Clin Exp Med; 2009 Jun; 9(2):113-6. PubMed ID: 19184328
[TBL] [Abstract][Full Text] [Related]
11. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
12. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional role of Gly281 in L-asparaginase from Erwinia carotovora.
Kotzia GA; Labrou NE
Protein Pept Lett; 2013 Dec; 20(12):1302-7. PubMed ID: 24261975
[TBL] [Abstract][Full Text] [Related]
14. Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.
Moola ZB; Scawen MD; Atkinson T; Nicholls DJ
Biochem J; 1994 Sep; 302 ( Pt 3)(Pt 3):921-7. PubMed ID: 7945221
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
16. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.
Cantor JR; Yoo TH; Dixit A; Iverson BL; Forsthuber TG; Georgiou G
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1272-7. PubMed ID: 21209329
[TBL] [Abstract][Full Text] [Related]
18. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
19. Designing an efficient multi-epitope peptide vaccine against Vibrio cholerae via combined immunoinformatics and protein interaction based approaches.
Nezafat N; Karimi Z; Eslami M; Mohkam M; Zandian S; Ghasemi Y
Comput Biol Chem; 2016 Jun; 62():82-95. PubMed ID: 27107181
[TBL] [Abstract][Full Text] [Related]
20. Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry.
Gervais D; King D; Kanda P; Foote N; Elliott L; Brown P; Lee NO; Thalassinos K; Pizzey C; Rambo R; Minshull TC; Dickman MJ; Smith S
Pharm Res; 2015 Nov; 32(11):3636-48. PubMed ID: 26040662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
